Back to mobile site

More on DNTH

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Dianthus Therapeutics (NQ:DNTH)
Delayed: 82.49 +0.60 (0.73%)
Prev. Close $81.89  
Open$83.64 
52 Wk High$ 
52 Wk Low$ 
Day High$85.00 
Day Low$79.79 
P/E N/A  
EPS$ 
Volume2,478,108 

Friends, Peers and Foes (?): TOI, ALNY, ARGX, BBIO, BIIB (more...)

Jun 18, 2026 04:30 PM Form 4 Dianthus Therapeutics, For: Jun 17 Filed by: Veness Adam M
Jun 17, 2026 04:33 PM Form 144 Dianthus Therapeutics, Filed by: Veness Adam M
Jun 12, 2026 02:53 PM Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'
Jun 12, 2026 07:01 AM Form 8-K Dianthus Therapeutics, For: Jun 12
Jun 10, 2026 04:10 PM Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
Jun 10, 2026 03:52 PM Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies
Jun 10, 2026 01:37 PM TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'
Jun 10, 2026 01:01 PM Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
Jun 10, 2026 10:40 AM Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'
Jun 10, 2026 10:38 AM Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
View All Articles

Entities mentioned with DNTH

View All Entities